Financial MilestonesMedincell may receive up to $117M in development and commercial milestones for mdc-TJK, in addition to royalties on all net sales of both mdc-TJK and the already-approved UZEDY™.
Product DevelopmentThe jointly developed MedinCell / Teva product candidate could be the first long-acting olanzapine with a favorable safety profile, since other LAIs of olanzapine have been associated with a black box warning on their FDA-authorized labels for post-injection delirium/sedation syndrome (PDSS), which severely limits their use.
Strategic PartnershipsMedincell announced the establishment of a strategic collaboration with AbbVie to co-develop and commercialize up to six therapeutic products across multiple therapeutic areas and indications, with potential to receive up to $1.9B in total potential development and commercial milestones, plus royalties on worldwide sales.